

# Miguel Urina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/480130/publications.pdf>

Version: 2024-02-01

49  
papers

39,708  
citations

134610

34  
h-index

206121

51  
g-index

57  
all docs

57  
docs citations

57  
times ranked

36387  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regional variability of glycemic control among adults with diabetes mellitus in Colombia. <i>Salud Publica De Mexico</i> , 2022, 64, 233-235.	0.1	0
2	Clinical, Microbiological, and Imaging Characteristics of Infective Endocarditis in Latin America: A Systematic Review. <i>International Journal of Infectious Diseases</i> , 2022, 117, 312-321.	1.5	7
3	Prospective evaluation of lipid management following acute coronary syndrome in <sc>non-Western</sc> countries. <i>Clinical Cardiology</i> , 2021, 44, 955-962.	0.7	5
4	The effect of comorbidities on glycemic control among Colombian adults with diabetes mellitus: a longitudinal approach with real-world data. <i>BMC Endocrine Disorders</i> , 2021, 21, 128.	0.9	14
5	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). <i>Archivos De Cardiologia De Mexico</i> , 2021, 92, .	0.1	4
6	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	1.2	58
7	Estimation of PQ distance dispersion for atrial fibrillation detection. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106167.	2.6	4
8	Statin associated adverse reactions in Latin America: a scoping review. <i>BMJ Open</i> , 2021, 11, e050675.	0.8	7
9	May Measurement Month 2018: an analysis of blood pressure screening results from Colombia. <i>European Heart Journal Supplements</i> , 2020, 22, H43-H46.	0.0	2
10	A Narrative Review and Expert Panel Recommendations on Dyslipidaemia Management After Acute Coronary Syndrome in Countries Outside Western Europe and North America. <i>Advances in Therapy</i> , 2020, 37, 1754-1777.	1.3	0
11	Las dislipidemias y su tratamiento en centros de alta complejidad en Colombia. <i>Clínica E Investigación En Arteriosclerosis</i> , 2020, 32, 101-110.	0.4	3
12	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
13	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , 2019, 394, 121-130.	6.3	1,625
14	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet</i> , 2019, 394, 131-138.	6.3	394
15	Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2780-2782.	1.2	30
16	Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. <i>Journal of Hypertension</i> , 2019, 37, 1126-1147.	0.3	29
17	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2018, 39, 363-370.	1.0	199
18	Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®. <i>Diabetologia</i> , 2018, 61, 1522-1527.	2.9	49

#	ARTICLE	IF	CITATIONS
19	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	1.6	347
20	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 205-218.	6.3	426
21	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	6.3	651
22	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 319-328.	6.3	628
23	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
24	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2755-2769.	3.0	148
25	Caracterizaci3n de un grupo de comit3s de 3tica en investigaci3n en Colombia. <i>Persona Y Bio3tica</i> , 2018, 22, 303-318.	0.2	2
26	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	1.0	112
27	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
28	Effect of interleukin-1 $\beta$ inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 1833-1842.	6.3	948
29	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	13.9	6,227
30	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
31	Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease. Results From EMPA-REG OUTCOME. <i>Circulation Journal</i> , 2017, 81, 227-234.	0.7	110
32	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1521-1532.	13.9	204
33	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	13.9	2,809
34	Risk Related to Pre-diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	260
35	Cause of Death and Predictors of All-cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	1.6	127
36	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). <i>Diabetes Care</i> , 2016, 39, 709-716.	4.3	55

#	ARTICLE	IF	CITATIONS
37	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 232-242.	13.9	2,188
38	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552
39	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the Arixaban for Prevention of Acute ISchemic Events 2 trial. American Heart Journal, 2015, 169, 531-538.	1.2	9
40	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	13.9	1,585
41	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2014, 312, 1006.	3.8	375
42	Angiotensinâ€“Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine, 2014, 371, 993-1004.	13.9	5,052
43	nâ€“3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine, 2012, 367, 309-318.	13.9	810
44	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	13.9	1,426
45	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine, 2012, 366, 1404-1413.	13.9	841
46	Use of Calcium Channel Blockers in Cardiovascular Risk Reduction. American Journal of Cardiovascular Drugs, 2010, 10, 143-154.	1.0	6
47	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 2008, 359, 2195-2207.	13.9	5,712
48	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial) Tj ETQq0 0 0 rBT /Overlook 10 Tf 5		
49	El plagio, su detecci3n y como prevenirlo en la literatura m3dica. Ciencia E Innovaci3n En Salud, 0, , .	0.0	0